Dr. Aaron Gerds presents results from the Phase 2 ACE-536-MF-001 study, demonstrating that luspatercept improves anemia in patients with myelofibrosis—with or without transfusion dependence—and shows encouraging activity when combined with ruxolitinib, with a manageable safety profile and no new safety signals.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.